This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
DaVita (DVA) Q1 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
DaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1.
DaVita HealthCare (DVA) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 16.11% and -0.22%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by net dialysis and the related lab patient service segment are likely to have aided DaVita's (DVA) top line in the first quarter.
DaVita (DVA) Partners With Fresenius, Boost Home Dialysis Care
by Zacks Equity Research
DaVita's (DVA) recent collaboration will help patients benefit from the portability, dependability and flexibility of NxStage home machines, designed to be easy to use.
6 Reasons Why Select Medical (SEM) Stock Looks Attractive
by Zacks Equity Research
Select Medical's (SEM) prolific lines of business, top-line growth, proven financial performance and strong cash flow, inorganic growth profile, partnerships with healthcare system giants bode well.
DaVita HealthCare (DVA) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain DaVita (DVA) in Your Portfolio Now
by Zacks Equity Research
Investors' confidence is high on the DaVita (DVA) stock, thanks to solid prospects.
DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
DaVita's (DVA) bottomline in Q4 declines year over year.
New Strong Sell Stocks for February 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
DaVita HealthCare (DVA) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -9.73% and -1.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by net dialysis and the related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the fourth quarter.
3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well positioned to gain from the prospects.
NextGen's (NXGN) Platform Gets Adopted by FPA Women's Health
by Zacks Equity Research
FPA Women's Health utilizes NextGen's (NXGN) Virtual Visits, which are integral to the company's Patient Experience Platform
Why You Should Retain Veeva (VEEV) in Your Portfolio Now?
by Zacks Equity Research
Investor confidence/optimism is high on Veeva (VEEV) stock, driven by its solid prospects.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, driven by its solid prospects.
Is DaVita HealthCare (DVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Here's Why You Must Add Accuray (ARAY) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Accuray (ARAY) stock, courtesy of its solid prospects.
Align (ALGN) Rides on Robust Invisalign Sales Amid Coronavirus
by Zacks Equity Research
Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.
CVS Health's (CVS) Front Store Sales Robust, LTC Suffers
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits arm benefits from strong Medicare annual enrollment period.
Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.
Quest Diagnostics (DGX) Ties Up With Hackensack Meridian Health
by Zacks Equity Research
Quest Diagnostics (DGX) collaborates with Hackensack Meridian Health to manage laboratory operation and provide high-quality healthcare network.
Select Medical (SEM) Rides on a Diversified Business Profile
by Zacks Equity Research
Select Medical's (SEM) supremacy in a fragmented market and its affordable healthcare services in each of its business segments bode well for the long haul.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Allscripts (MDRX) stock on the back of its solid prospects.
New Strong Buy Stocks for December 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: